CD93 and Miyoshi myopathy: Since CD93 and CD69 were clear biomarkers of Bz sensitivity in the mouse system, we next sought to determine whether these markers are expressed in human MM and whether they are associated with differences in outcome in clinical trials of patients being treated with Bz.